NIVALENOL


Synonyms	Nivalenol
UNII	5WOP02RM1U
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	UKOTXHQERFPCBU-XBXCNEFVSA-N
Smiles	CC1=C[C@H]2O[C@@H]3[C@H](O)[C@@H](O)[C@@](C)([C@]34CO4)[C@@]2(CO)[C@H](O)C1=O
InChI	InChI=1S/C15H20O7/c1-6-3-7-14(4-16,11(20)8(6)17)13(2)10(19)9(18)12(22-7)15(13)5-21-15/h3,7,9-12,16,18-20H,4-5H2,1-2H3/t7-,9-,10-,11-,12-,13-,14-,15+/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H20O7
Molecular Weight	312.32
AlogP	-2.08
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	1.0
Polar Surface Area	119.75
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	22.0

Assay Description	Organism	Bioactivity
Phytotoxicity against Arabidopsis thaliana Col-4 leaves assessed as induction of chlorosis at 100 uM after 7 weeks post compound application by detached leaf assay	Arabidopsis thaliana	10.0 %
Phytotoxicity against Arabidopsis thaliana Col-4 leaves assessed as induction of chlorosis, shriveling or death of leaves after 7 weeks post compound application by detached leaf assay	Arabidopsis thaliana	100.0 uM
Phytotoxicity against Arabidopsis thaliana Col-4 leaves assessed as induction of leaf death after 7 weeks post compound application by detached leaf assay	Arabidopsis thaliana	100.0 uM

Cross References

Resources	Reference
ChEMBL	CHEMBL509655
FDA SRS	5WOP02RM1U
PubChem	5284433
ZINC	ZINC12496319

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).